Second primary vs. primary bowel malignancies
Data about copy number aberrations was obtained from primary CRC (n=90). DNA was collected from second primary CRC (in HL survivors, n = 39), and primary SBA (n=14). For second primary SBA (in HL and TC survivors), DNA was isolated for molecular analyses (n=7). Copy number aberrations were evaluated after low-coverage whole genome sequencing.
- 60 samples
- DAC: EGAC00001001051
- Technology: Illumina HiSeq 4000
Data Access Policy of NKI-AvL TGO
Data Access Policy of NKI-AvL TGO To request access to this specific dataset, and in order to comply with local and (inter)national regulations, please follow the steps described below: 1. Please fill in the information requested on the website: ega.nki.nl 2. Once you’ve submitted this information, the Data Access Committee (DAC) and the NKI-AVL Internal Review Board (IRB) will review your planned study and its goals and judge whether it is competing with our interests. The DAC and IRB can approve or decline your request or request a modification. 3. Upon approval by the IRB, you will receive a Data Transfer Agreement (DTA) that needs to be filled in and signed by the legal representative of your institute / company. 4. Upon acceptance of a signed DTA by our Knowledge Transfer & Contracting Office (KT&C), your party will receive a copy signed by our legal representative, and you will need to submit your access request via the EGA website
Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.
| Study ID | Study Title | Study Type |
|---|---|---|
| Cancer Genomics |